SubscribeSign In
LeaderPortfolio
Billionaire Profile
Wu Yiling
Global Rank
#1734

Image: SY | CC BY-SA 4.0 | via Wikimedia Commons

Wu Yiling

CEO, Pharmaceuticals
CHINA
Real-Time Net Worth
$2.41B
Estimated based on Pharmaceuticals stock value as of June 4, 2026
-1.69% (24h)
Age
76
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
CHINA

Biography

Wu Yiling, born in 1949, is a Chinese billionaire and the honorary chairman of Yiling Pharmaceutical. His wealth stems from his stake in the company, which was founded in 1992. With a background in both Western and Traditional Chinese Medicine (TCM), Wu transitioned from practicing TCM for 11 years to building a pharmaceutical empire. Yiling Pharmaceutical's flagship product, Lianhua Qingwen capsules, gained international recognition during the COVID-19 pandemic. Wu's career highlights a blend of clinical pragmatism and entrepreneurial drive, making him a prominent figure in China's healthcare industry. As of March 10, 2026, his net worth is estimated at $2.5 billion, derived primarily from his ownership in Yiling Pharmaceutical.

Fact Checked
Verified by Editorial Team
Live Data
Updated 6/4/2026
Report a Correction

Wealth Over Time

Career Milestones

  1. 1

    Founded Yiling Pharmaceutical

    Wu established Yiling Pharmaceutical, a company focused on traditional Chinese medicine.

  2. 2

    Yiling Pharmaceutical IPO

    Yiling Pharmaceutical went public on the Shenzhen Stock Exchange.

  3. 3

    Lianhua Qingwen Capsules Recognition

    Lianhua Qingwen capsules gained international attention during the COVID-19 pandemic.

Net Worth History

YearNet Worth
2026$2.41B
2025$2.6B
2024$2.5B

Philanthropy

COVID-19 Relief

$$7.9M
Healthcare

Donation of Lianhua Qingwen capsules to Shanghai and Wuhan during the COVID-19 pandemic.

Controversies & Legal

2022

Questions over Covid-19 Treatment Efficacy

Controversy arose concerning the efficacy of Lianhua Qingwen capsules, leading to a significant drop in the company's stock price.

In-Depth Profile

Early Life

Wu Yiling was born in 1949 in China. His early life was influenced by his family's medical background, as his father was a doctor. He earned medical degrees from Hebei Medical University and Nanjing University of Chinese Medicine, gaining expertise in both Western and traditional Chinese medicine.

Rise to Success

After practicing traditional Chinese medicine for 11 years, Wu founded Yiling Pharmaceutical in 1992. The company focused on developing medications based on TCM principles. A key product, Lianhua Qingwen capsules, gained international attention during the COVID-19 pandemic. The capsules were recommended by Chinese health experts for treating mild cases of the virus, which boosted the company's revenue and expanded its global reach.

Key Business Strategies

Yiling Pharmaceutical's success is rooted in a strategy combining traditional Chinese medicine with modern pharmaceutical standards. Wu's leadership style incorporates clinical pragmatism, prioritizing real-world efficacy in drug development. The company's focus on innovative R&D, with significant investments, has been a key element of its growth. Yiling Pharmaceutical has expanded its product portfolio to include modern traditional Chinese medicine, chemical pharmacy, and health care products.

Philanthropy

While specific details about Wu Yiling's philanthropy are limited, it's known that he is dedicated to charitable causes. During the COVID-19 pandemic, Yiling Pharmaceutical donated Lianhua Qingwen capsules to support medical efforts, both domestically and internationally.

Career Milestones

1992

Founded Yiling Pharmaceutical

Wu established Yiling Pharmaceutical, a company focused on traditional Chinese medicine.

2011

Yiling Pharmaceutical IPO

Yiling Pharmaceutical went public on the Shenzhen Stock Exchange.

2020

Lianhua Qingwen Capsules Recognition

Lianhua Qingwen capsules gained international attention during the COVID-19 pandemic.

Philanthropy & Social Impact

Healthcare

COVID-19 Relief

$7.9M

Donation of Lianhua Qingwen capsules to Shanghai and Wuhan during the COVID-19 pandemic.

Controversies & Challenges

2022

Questions over Covid-19 Treatment Efficacy

Controversy arose concerning the efficacy of Lianhua Qingwen capsules, leading to a significant drop in the company's stock price.

Compare Wu Yiling

Net Worth Face-off
Wu Yiling vs Elon Musk
Compare Wealth →
Net Worth Face-off
Wu Yiling vs Jeff Bezos
Compare Wealth →
Net Worth Face-off
Wu Yiling vs Mark Zuckerberg
Compare Wealth →